-
UNDERSTANDING EVIDENCE AND REIMBURSEMENT PATHWAYS FOR ONCOLOGY RETREATMENT: A CROSS-COUNTRY ASSESSMENT OF REGULATORY, GUIDELINE, AND HTA PERSPECTIVES
Aug 11, 2026, 17:15 PM -
ADDITIVE VERSUS MULTIPLICATIVE MODELS FOR CONTINUOUS OUTCOMES IN BAYESIAN META-ANALYSIS: IMPLICATIONS FOR EVIDENCE SYNTHESIS IN POSTOPERATIVE PAIN
Aug 11, 2026, 17:15 PM -
COMPARISON OF THE PSYCHOMETRIC PROPERTIES OF THE 3-ITEM AND 23-ITEM VERSIONS OF THE CLINICIAN ADMINISTERED DISSOCIATIVE STATES SCALE (CADSS)
Aug 11, 2026, 17:15 PM -
REPRESENTATIVENESS OF BROAD-CONSENT REAL-WORLD DATA: A CROSS-SECTIONAL ANALYSIS OF 3.5 MILLION INPATIENTS IN THE HELIOS SAFE MEDICAL DATA PLATFORM
Aug 11, 2026, 17:15 PM -
LIFETIME CLINICAL AND ECONOMIC IMPACT OF EARLY VERSUS DELAYED GLP-1 RECEPTOR AGONIST INITIATION ACROSS RISK-STRATIFIED TYPE 2 DIABETES POPULATIONS IN THE UAE: A CORE DIABETES MODEL ANALYSIS
Aug 11, 2026, 17:15 PM -
BEYOND THE ICER: ASSESSING THE UPTAKE OF BROADER VALUE OUTCOMES IN FRENCH HTA APPRAISALS
Aug 11, 2026, 17:15 PM -
FROM LEARNING TO PRACTICE: DEVELOPING AN EDUCATIONAL FEEDBACK FRAMEWORK BASED ON TRAINING TRANSFER EVALUATION
Aug 11, 2026, 17:15 PM -
STRUCTURAL UNCERTAINTY IN MODEL-BASED ECONOMIC EVALUATIONS: A COMPARATIVE REVIEW OF TECHNOLOGY APPRAISALS FROM NICE AND HAS OVER 2014-2026
Aug 11, 2026, 17:15 PM -
HEALTHCARE-RESOURCE UTILIZATION RELATED TO THE MANAGEMENT OF C3 GLOMERULOPATHY IN BRAZIL: ANALYSIS FROM THE PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
Aug 11, 2026, 17:15 PM -
CLINICAL AND ECONOMIC IMPACT OF SWITCHING PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA CONTROLLED ON BENRALIZUMAB TO DEPEMOKIMAB IN THE UNITED STATES
Aug 11, 2026, 17:15 PM -
DEMAND AND WILLINGNESS TO PAY FOR THE DENGUE VACCINE AMONG ADULTS IN HUE CITY, CENTRAL VIETNAM: A CONTINGENT VALUATION STUDY
Aug 11, 2026, 17:15 PM -
SYSTEMATIC LITERATURE REVIEW OF CLINICAL EVIDENCE FOR ELAMIPRETIDE IN BARTH SYNDROME
Aug 11, 2026, 17:15 PM -
LINKING FRENCH HOSPITAL DISCHARGE DATA TO OPEN-SOURCE EXPOSOME DATA : A USE CASE ON COPD AND ASTHMA
Aug 11, 2026, 17:15 PM -
IDENTIFYINGWHETHER COST OR CLINICAL OUTCOMES DRIVE HETEROGENEITY: THE COST-EFFECTIVENESS VARIABILITY INDEX (CEVI)
Aug 11, 2026, 17:15 PM -
CLINICAL AND ECONOMIC VALUE OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE VERSUS 14-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PEDIATRIC POPULATIONS: A MULTI-COUNTRY COST-EFFECTIVENESS ANALYSIS
Aug 11, 2026, 17:15 PM -
REAL-WORLD TREATMENT PATTERNS AND LINE-TO-LINE TRANSITIONS IN MULTIPLE MYELOMA IN POLAND: A POLICY-ALIGNED ANALYSIS OF PUBLICLY AVAILABLE NATIONAL HEALTH FUND (NFZ) DATA
Aug 11, 2026, 17:15 PM -
WHAT MATTERS BEYOND MODEL ARCHITECTURE? SPONSORSHIP, RISK EXTRAPOLATION, AND FAVOURABLE CONCLUSIONS IN EVALUATIONS OF NEWER TYPE 2 DIABETES THERAPIES
Aug 11, 2026, 17:15 PM -
THE HEALTH CARE RESOURCE UTILIZATION (HCRU) AND CLINICAL BURDEN OF HEMOLYTIC DISEASE OF THE FETUS AND NEWBORN (HDFN) IN EUROPE - FINDINGS FROM A REAL-WORLD SURVEY
Aug 11, 2026, 17:15 PM -
BUILDING SOCIAL CAPITAL AND HEALTH LITERACY THROUGH THE COMMUNITY LIVING ROOM PROGRAMME: EVIDENCE FROM HONG KONG'S SUBDIVIDED UNIT RESIDENTS
Aug 11, 2026, 17:15 PM -
SOCIETAL IMPACT OF A DISEASE - THE CASE OF HEMOPHILIA A. EVIDENCE FROM A DANISH NATIONAL REGISTER STUDY
Aug 11, 2026, 17:15 PM
